Genotypes of Epstein–Barr virus in immunocompromised of Diyala, Iraq

Background: The Epstein-Barr Virus ( EBV) represents a significant etiological agent of acute cervical lymphadenitis amongst viruses. The clinical manifestations of acute Epstein-Barr virus infection intersect with those of numerous other infectious and non-infectious disorders; thus, dependable laboratory testing is essential for both confirmation and differential diagnosis. Two variants of the Epstein-Barr virus exist. Despite the similarity of their genomes, the areas harbouring the EBNA genes exhibit differences. The EBV may reactivate and proliferate with lethal consequences in immunocompromised individuals, infecting 90% of the global population. Nonetheless, particular attributes of the EBV infection epidemic phase remain unrecognized. Aim: The objectives of the current study were to identify the EBV genotypes and assess the correlation between EBV and immune-deficient individuals in Diyala Governorate. Methods: One hundred blood plasma samples were collected from (100) Immunocompromised patients and (50) healthy blood donors. All subjects endure. Serological testing employing the enzyme-linked immunosorbent assay (ELISA) is utilized to identify the existence of anti-EBV IgM and anti-EBV IgG in blood samples; subsequently, all plasma samples exhibiting positive anti-EBV IgM and anti-EBV IgG are utilized for the identification of EBV DNA utilizing RT-PCR. Results: Only 21/100 specimens of immunecompromised patients have positive serology, (4) for EBV IgM and (17) for EBV IgG and all healthy group was negative 0/50, and 1/21 was positive in RT-PCR for EBNA2C gene. Conclusion: We conclude that the detection and typing of EBNA-2 may be conducted using peripheral blood samples, and the elevated prevalence of this type in our cases suggests that this population was indeed at risk of developing lymphoproliferative disorders and should be followed.